Effect of Extracorporeal Shockwave Therapy on Pruritus in Neurodermatitis Patients

NCT07206680 | Completed

• 1 other identifier: P.T.REC/012/005978
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the therapeutic effect of shockwave therapy on reducing pruritus in neurodermatitis patients.

Conditions

Neurodermatitis

Outcome Measures

Primary Outcomes (1)

• 5-D Itching Scale

  The 5-D Itching Scale will be used to assess the improvement of cases by evaluating pruritus severity. Patients will complete the scale both before starting the treatment and at four sessions following the treatment. The following steps will be followed during the assessment: the patient will be positioned comfortably (sitting position), the physiotherapist will explain the pruritus symptoms score to the patient, and the patient will determine their points on the 5-D itch scale.

  one month

Study Arms (2)

Shockwave therapy + corticosteroids + emollients

EXPERIMENTAL

It will include 17 patients suffering from neurodermatitis who will receive shockwave therapy for 10min, 4 sessions, once per week and emollients \& corticosteroids for a month.

Device: Shockwave therapy; Drug: Emollients & corticosteroids

Corticosteroids & Emollients

ACTIVE COMPARATOR

It will include 17 patients suffering from neurodermatitis who will receive their emollients \& corticosteroids only for a month.

Drug: Emollients & corticosteroids

Interventions

Shockwave therapy DEVICE

The procedures for Extracorporeal Shockwave Therapy (ESWT) involve several steps. First, the patient is positioned comfortably, and the physiotherapist explains the treatment procedure. Before the session begins, the device cables are checked for proper functioning. The shockwave type used is Non-Focused/Radial, with a treatment duration not exceeding 10 minutes. The frequency is set at 4 Hz, and the intensity ranges from 0.05 to 0.20 mJ/mm². Each session involves a total of 1000 to 2000 shocks. The treatment consists of four sessions, each held once a week.

Shockwave therapy + corticosteroids + emollients

Emollients & corticosteroids DRUG

Patients in both groups will receive emollients \& corticosteroids for one month.

Corticosteroids & Emollients; Shockwave therapy + corticosteroids + emollients

Eligibility Criteria

• Age: 55 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age range between 55:75 years.
• Male and female patients will participate in the study.
• All patients have neurodermatitis.
• All patients will be received the same approach of medication and nursing care.
• All patients enrolled in the study will have their informed consent.

You may not qualify if:

• Patients diagnosed with cancer.
• Pregnant woman.
• active infection.
• Patients with any systemic diseases that may interfere with the objectives of the study.
• Cardiac pacemakers or other implantable devices.
• Current anticoagulation use.
• Any other cause of itching

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

Suez Canal University Hospital

Ismailia, Egypt

Location

MeSH Terms

Conditions

Neurodermatitis

Interventions

Extracorporeal Shockwave Therapy; Emollients; Adrenal Cortex Hormones

Condition Hierarchy (Ancestors)

Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous

Intervention Hierarchy (Ancestors)

Ultrasonic Therapy; Diathermy; Hyperthermia, Induced; Therapeutics; Physical Therapy Modalities; Rehabilitation; Dermatologic Agents; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

• Nessrien Afify Abd El Rashid, PhD

  Assistant Professor, Cairo University

  STUDY CHAIR

• Noha Zakaria Tawfik, PhD

  Assistant Professor, Suez Canal University

  STUDY DIRECTOR

• Doaa Atef Aly, PhD

  Lecturer, Cairo university

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 26, 2025
• First Posted: October 3, 2025
• Study Start: December 15, 2024
• Primary Completion: September 15, 2025
• Study Completion: October 25, 2025
• Last Updated: March 9, 2026

Record last verified: 2025-09

Locations

EG (1)